Dairy Products and Heart Risk in Adults with Severe Obesity
Compares whole dairy, polar-lipid-enriched dairy and low-fat dairy in adults with severe obesity.
Plain-language title generated from the registry record
Registry title: Dairy Lipids and Cardiometabolic Risk
Key facts
- Where
- Pierre-Bénite, FranceSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05783466, who can take part
Where in France
- Centres Hospitalier Lyon Sud, Service d'Endocrinologie-Diabète-NutritionPierre-Bénite, FranceTaking people
- Centre de Recherche en Nutrition Humaine Rhone-AlpesPierre-Bénite, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT05783466
- Record updated
- 18 June 2025
- Original description
It is a randomized parallel arm intervention study in adults with severe obesity. The objective is to demonstrate that within a dietary handling for weight loss, the daily ingestion during 3 months of whole dairy products enriched with milk polar lipids or whole dairy products decreases to a greater extent fasting plasma apolipoprotein B concentrations than the daily ingestion of low-fat dairy products (control group).Read full original descriptionShow less
Bioactive Dairy Lipids to Manage Cardiometabolic Risk in Obesity
It is a randomized parallel arm intervention study in adults with severe obesity. The objective is to demonstrate that within a dietary handling for weight loss, the daily ingestion during 3 months of whole dairy products enriched with milk polar lipids or whole dairy products decreases to a greater extent fasting plasma apolipoprotein B concentrations than the daily ingestion of low-fat dairy products (control group).
Metabolic parameters will be assessed before and after the 3-month intervention, both at fasting and in postprandial period after the consumption of standardized meals.
Inclusion: Men and women between 18-70 years; Body Mass Index (BMI) between 35 and 60 kg/m2 inclusive; Stable body weight (weight change +/- 5 % for 3 months prior to screening); Consumption of at least 1 serving/day of dairy products made from cow's milk; Informed consent.
Exclusion: Treated with lipid lowering drugs (fibrates, statins, anti-PCSK9, ezetimibe, cholestyramine) within the last 6 weeks before study entry; Treated with insulin, GLP-1 analogs, acarbose, corticoids, beta-blockers; Medications interfering with intestinal microbiota (beta-lactamines within 3 months before the study or laxatives); History of bariatric or digestive surgery or disease interfering with main outcomes; Food allergies or intolerance to dairy products; Drinking more than 3 glasses of alcohol per day (>30g/day); Pregnancy, parturiency or breastfeeding; Dietary restriction (vegetarian or lactovegetarian) or high protein diet; Use of dietary supplements; Smoking ≥ 5 cigarettes/day during the past 6 months.